Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

347.64
Delayed Data
As of 4:00pm ET
 +5.23 / +1.53%
Today’s Change
244.28
Today|||52-Week Range
348.84
+9.13%
Year-to-Date
What's in the Cards for Biogen (BIIB) This Earnings Season?
10:07am / Zacks.com - Paid Partner Content
M&A Rumors Rise Again
Jan 19 / TheStreet.com - Paid Partner Content
Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips
9:41am / Zacks.com - Paid Partner Content
Five Cheap Stocks With Growing Book Value
Jan 18 / GuruFocus News - Paid Partner Content
Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?
9:19am / Zacks.com - Paid Partner Content
Charter Trust Co Buys iShares Core MSCI Emerging Markets, The Home Depot Inc, iShares...
Jan 17 / GuruFocus News - Paid Partner Content
Sanofi Strikes $11.6 Billion Deal for Bioverativ
5:29am / TheStreet.com - Paid Partner Content
Legacy Private Trust Co. Buys iShares 20+ Year Treasury Bond ETF, SPDR Bloomberg Barc...
Jan 16 / GuruFocus News - Paid Partner Content
Catawba Capital Management Buys Automatic Data Processing Inc, Parker Hannifin Corp,...
Jan 19 / GuruFocus News - Paid Partner Content
3 Pharma and Biotech Stocks to Watch Out for in 2018
Jan 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close342.41
Today’s open343.59
Day’s range342.03 - 347.82
Volume1,195,213
Average volume (3 months)1,224,738
Market cap$72.4B
Data as of 4:00pm ET, 01/22/2018

Growth & Valuation

Earnings growth (last year)+10.32%
Earnings growth (this year)+8.81%
Earnings growth (next 5 years)+6.00%
Revenue growth (last year)+9.37%
P/E ratio21.3
Price/Sales6.09
Price/Book6.09

Competitors

 Today’s
change
Today’s
% change
ILMNIllumina Inc+1.64+0.67%
GILDGilead Sciences+0.43+0.53%
----
BIVVBioverativ Inc+39.68+61.89%
Data as of 4:00pm ET, 01/22/2018

Financials

Next reporting dateJanuary 25, 2018
EPS forecast (this quarter)$5.45
Annual revenue (last year)$10.2B
Annual profit (last year)$3.7B
Net profit margin36.32%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Michel Vounatsos
Senior Vice President-
US Therapeutic Operations
Alisha A. Alaimo
Corporate headquarters
Cambridge, Massachusetts

Forecasts